Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.
Cancer
AbbVie’s Elahere wins European approval for certain ovarian cancers
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
Uppsala and KTH Royal develop antibody for potential cancer treatment
Alpha-9 becomes latest radiopharma to secure funds with $175m Series C
ImmunoPrecise touts potential of rabbit monoclonal antibodies in oncology
FDA approves Astellas’ VYLOY for gastric cancer treatment
Sanofi and Orano Med link for radioligand therapy development
